Major depressive disorder is a genetic susceptible disease, and a psychiatric syndrome with a high rate of incidence and recurrence. Because of its complexity concerning etiology and pathogenesis, the cure rate of first-line antidepressants is low. In recent years, accumulative evidences revealed that oxytocin act as a physiological or pathological participant in a variety of complex neuropsychological activities, including major depressive disorder. Six electronic databases (Web of Science, PubMed, Scopus, Google Scholar, CNKI, and Wanfang) were employed for researching relevant publications. At last, 226 articles were extracted. The current review addresses the correlation of the oxytocin system and major depressive disorder. Besides, we summarize the mechanisms by which the oxytocin system exerts potential antidepressant effects, including regulating neuronal activity, influencing neuroplasticity and regeneration, altering neurotransmitter release, down regulating hypothalamic–pituitary–adrenal axis, anti-inflammatory, antioxidation, and genetic effects. Increasing evidence shows that oxytocin and its receptor gene may play a potential role in major depressive disorder. Future research should focus on the predictive ability of the oxytocin system as a biomarker, as well as its role in targeted prevention and early intervention of major depressive disorder.

中文翻译：

---

催产素与重度抑郁症的关系：抗抑郁药混杂作用的作用

重度抑郁症是一种遗传易感性疾病，是一种高发病率和高复发率的精神综合征。由于其病因病机复杂，一线抗抑郁药治愈率较低。近年来，越来越多的证据表明，催产素在包括重度抑郁症在内的多种复杂的神经心理活动中充当生理或病理参与者。六个电子数据库（Web of Science、PubMed、Scopus、Google Scholar、CNKI 和万方）被用于研究相关出版物。最终提取出226篇文章。目前的审查解决了催产素系统与重度抑郁症的相关性。此外，我们总结了催产素系统发挥潜在抗抑郁作用的机制，包括调节神经元活动、影响神经可塑性和再生、改变神经递质释放、下调下丘脑-垂体-肾上腺轴、抗炎、抗氧化和遗传效应。越来越多的证据表明，催产素及其受体基因可能在重度抑郁症中发挥潜在作用。未来的研究应侧重于催产素系统作为生物标志物的预测能力，以及其在重度抑郁症的靶向预防和早期干预中的作用。越来越多的证据表明，催产素及其受体基因可能在重度抑郁症中发挥潜在作用。未来的研究应侧重于催产素系统作为生物标志物的预测能力，以及其在重度抑郁症的靶向预防和早期干预中的作用。越来越多的证据表明，催产素及其受体基因可能在重度抑郁症中发挥潜在作用。未来的研究应侧重于催产素系统作为生物标志物的预测能力，以及其在重度抑郁症的靶向预防和早期干预中的作用。